Compare POET & SANA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | POET | SANA |
|---|---|---|
| Founded | 1972 | 2018 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | 2008 | 2021 |
| Metric | POET | SANA |
|---|---|---|
| Price | $14.10 | $3.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.80 |
| AVG Volume (30 Days) | ★ 59.8M | 3.8M |
| Earning Date | 08-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 17.24 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $848.96 | N/A |
| Revenue Next Year | $700.00 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.87 | $1.98 |
| 52 Week High | $20.65 | $6.55 |
| Indicator | POET | SANA |
|---|---|---|
| Relative Strength Index (RSI) | 57.84 | 39.07 |
| Support Level | $5.50 | $2.88 |
| Resistance Level | $15.50 | $3.43 |
| Average True Range (ATR) | 2.05 | 0.21 |
| MACD | 0.63 | -0.05 |
| Stochastic Oscillator | 55.11 | 12.58 |
POET Technologies Inc is a design and development company offering high-speed optical engines, light source products, and custom optical modules to the artificial intelligence systems market and hyperscale data centers. Its integration solutions are based on the POET Optical Interposer, a novel, patented platform that allows the seamless integration of electronic and photonic devices into a single chip using wafer-level semiconductor manufacturing techniques. POET's Optical Interposer platform also solves device integration challenges across a broad range of communication, computing, and sensing applications. The company operates geographically in the United States, Canada, Singapore and China.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.